380 related articles for article (PubMed ID: 20632403)
1. Healthcare costs within a year of respiratory syncytial virus among Medicaid infants.
Palmer L; Hall CB; Katkin JP; Shi N; Masaquel AS; McLaurin KK; Mahadevia PJ
Pediatr Pulmonol; 2010 Aug; 45(8):772-81. PubMed ID: 20632403
[TBL] [Abstract][Full Text] [Related]
2. Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants.
Shi N; Palmer L; Chu BC; Katkin JP; Hall CB; Masaquel AS; Mahadevia PJ
J Med Econ; 2011; 14(3):335-40. PubMed ID: 21524154
[TBL] [Abstract][Full Text] [Related]
3. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
Stewart DL; Romero JR; Buysman EK; Fernandes AW; Mahadevia PJ
Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
[TBL] [Abstract][Full Text] [Related]
5. Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life.
Escobar GJ; Ragins A; Li SX; Prager L; Masaquel AS; Kipnis P
Arch Pediatr Adolesc Med; 2010 Oct; 164(10):915-22. PubMed ID: 20921348
[TBL] [Abstract][Full Text] [Related]
6. Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life.
Forbes ML; Hall CB; Jackson A; Masaquel AS; Mahadevia PJ
J Med Econ; 2010 Mar; 13(1):136-41. PubMed ID: 20128663
[TBL] [Abstract][Full Text] [Related]
7. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
Simoes EA; Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
[TBL] [Abstract][Full Text] [Related]
8. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
9. Recurrent wheezing after respiratory syncytial virus or non-respiratory syncytial virus bronchiolitis in infancy: a 3-year follow-up.
Valkonen H; Waris M; Ruohola A; Ruuskanen O; Heikkinen T
Allergy; 2009 Sep; 64(9):1359-65. PubMed ID: 19416146
[TBL] [Abstract][Full Text] [Related]
10. Outpatient RSV lower respiratory infections among high-risk infants and other pediatric populations.
Paramore LC; Mahadevia PJ; Piedra PA
Pediatr Pulmonol; 2010 Jun; 45(6):578-84. PubMed ID: 20503283
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
12. Impact of respiratory syncytial virus infection as a cause of lower respiratory tract infection in children younger than 3 years of age in Japan.
Kaneko M; Watanabe J; Kuwahara M; Ueno E; Hida M; Kinoshita A; Sone T
J Infect; 2002 May; 44(4):240-3. PubMed ID: 12099731
[TBL] [Abstract][Full Text] [Related]
13. Economic-Burden Trajectories in Commercially Insured US Infants With Respiratory Syncytial Virus Infection.
Chirikov VV; Simões EAF; Kuznik A; Kwon Y; Botteman M
J Infect Dis; 2020 Mar; 221(8):1244-1255. PubMed ID: 30982895
[TBL] [Abstract][Full Text] [Related]
14. Comparison of human metapneumovirus, respiratory syncytial virus and influenza A virus lower respiratory tract infections in hospitalized young children.
Wolf DG; Greenberg D; Kalkstein D; Shemer-Avni Y; Givon-Lavi N; Saleh N; Goldberg MD; Dagan R
Pediatr Infect Dis J; 2006 Apr; 25(4):320-4. PubMed ID: 16567983
[TBL] [Abstract][Full Text] [Related]
15. Healthcare resource utilization and costs in the 12 months following hospitalization for respiratory syncytial virus or unspecified bronchiolitis among infants.
Ledbetter J; Brannman L; Wade SW; Gonzales T; Kong AM
J Med Econ; 2020 Feb; 23(2):139-147. PubMed ID: 31432723
[No Abstract] [Full Text] [Related]
16. Respiratory outcomes, utilization and costs 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infants.
Palmer L; Hall CB; Katkin JP; Shi N; Masaquel AS; McLaurin KK; Mahadevia PJ
Curr Med Res Opin; 2011 Feb; 27(2):403-12. PubMed ID: 21192761
[TBL] [Abstract][Full Text] [Related]
17. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study.
Henderson J; Hilliard TN; Sherriff A; Stalker D; Al Shammari N; Thomas HM
Pediatr Allergy Immunol; 2005 Aug; 16(5):386-92. PubMed ID: 16101930
[TBL] [Abstract][Full Text] [Related]
18. Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy.
Bradley JP; Bacharier LB; Bonfiglio J; Schechtman KB; Strunk R; Storch G; Castro M
Pediatrics; 2005 Jan; 115(1):e7-14. PubMed ID: 15629968
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality.
Howard TS; Hoffman LH; Stang PE; Simoes EA
J Pediatr; 2000 Aug; 137(2):227-32. PubMed ID: 10931416
[TBL] [Abstract][Full Text] [Related]
20. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
Marchetti A; Lau H; Magar R; Wang L; Devercelli G
Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
